EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring Thoracic Radiotherapy in Metastatic NSCLC: A Retrospective Review in the Era of Immunotherapy and Targeted Therapies

Sina Mansoorian, Janina Lehmann, Lukas Käsmann, Richard Gaus, Cedric Richlitzki, Helene Kravutske, Florian Putz, Nina-Sophie Schmidt-Hegemann, Niels Reinmuth, Amanda Tufman, Julien Dinkel, Gabriel Sheikh und 2 weitere

Clinical Lung Cancer · 2026-05 · 27 (4) · 54-64.e1

DOI: 10.1016/j.cllc.2026.02.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2026-05. Verfasst von Sina Mansoorian und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lung cancer remains the leading cause of cancer-related deaths worldwide. Advances in immunotherapy and targeted therapies have improved survival in stage IV non-small cell lung cancer (NSCLC), highlighting the importance of local control of the primary tumor. Hypofractionated radiotherapy (hypo-RT), delivering high biologically effective doses (BEDs) over shorter durations, shows potential in locally advanced NSCLC but is underexplored in metastatic settings. PURPOSE: This retrospective study evaluated 104 patients with stage IV NSCLC who received hypo-RT to the primary tumor at LMU Munich between December 2013 and June 2022. The primary endpoints were overall survival (OS) and progression-free survival (PFS), while the secondary endpoints included local failure-free survival, regional failure-free survival, distant failure-free survival, and the identification of prognostic factors. FINDINGS: Median OS and PFS were 15.4 months (95% confidence interval [CI]: 10.5-24.4) and 3.9 months (95% CI, 3.2-6.2), respectively. Significant predictors of OS included Eastern Cooperative Oncology Group performance status >1 (hazard ratio [HR]: 3.260, P = .0003), male sex (HR: 1.869, P = .038), metastases in >2 organ systems (HR: 2.014, P = .022), and BED < 58.5 Gy (HR: 2.117, P = .017). Predictors of PFS included smoking history

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapyHumansRetrospective StudiesMaleFemalePrognosisAgedMiddle AgedMolecular Targeted TherapyAged, 80 and overSurvival RateAdult

Stichwörter der Autor:innen

Biologically effective doseHypofractionated radiotherapyOverall survivalPrognostic factorsStage IV non–small cell lung cancer

Autor:innen und Institutionen

  • Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
  • Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Comprehensive Pneu…
  • TUM School of Computation, Information and Technology, Munich, Germany.
  • Department of Radiation Oncology, University Hospital, FAU Erlangen-Nürnberg, Erlangen, Germany.
  • German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Asklepios Lung Clinic Munich-Gauting, Member of the German Center for Lung Research (DZL), Munich, Ger…
  • German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), M…

Zitieren

APA

Mansoorian, S., Lehmann, J., Käsmann, L., Gaus, R., Richlitzki, C., Kravutske, H., Putz, F., Schmidt-Hegemann, N. S., Reinmuth, N., Tufman, A., Dinkel, J., Sheikh, G., Belka, C., & Eze, C. (2026). Exploring Thoracic Radiotherapy in Metastatic NSCLC: A Retrospective Review in the Era of Immunotherapy and Targeted Therapies. Clinical Lung Cancer, 27(4), 54-64.e1. https://doi.org/10.1016/j.cllc.2026.02.009

Vancouver

Mansoorian S, Lehmann J, Käsmann L, Gaus R, Richlitzki C, Kravutske H, et al. Exploring Thoracic Radiotherapy in Metastatic NSCLC: A Retrospective Review in the Era of Immunotherapy and Targeted Therapies. Clinical Lung Cancer. 2026;27(4):54-64.e1. doi:10.1016/j.cllc.2026.02.009

BibTeX
@article{Mansoorian2026,
  author = {Mansoorian, Sina and Lehmann, Janina and Käsmann, Lukas and Gaus, Richard and Richlitzki, Cedric and Kravutske, Helene and Putz, Florian and Schmidt-Hegemann, Nina-Sophie and Reinmuth, Niels and Tufman, Amanda and Dinkel, Julien and Sheikh, Gabriel and Belka, Claus and Eze, Chukwuka},
  title = {Exploring Thoracic Radiotherapy in Metastatic NSCLC: A Retrospective Review in the Era of Immunotherapy and Targeted Therapies},
  journal = {Clinical Lung Cancer},
  year = {2026},
  volume = {27},
  number = {4},
  pages = {54--64.e1},
  doi = {10.1016/j.cllc.2026.02.009}
}
Kostenlos starten →